Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.

@article{Poncet2008UseOT,
  title={Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.},
  author={B{\'e}n{\'e}dicte Poncet and Thomas Bachelot and Cyrille Colin and Christell Ganne and Isabelle Jaisson-Hot and Hubert Orfeuvre and Pierre-Yves P{\'e}aud and J. Ph. Jacquin and Bruno Salles and Jean-Dominique Tigaud and Isabelle Mechin-Cretinon and François Mar{\'e}chal and C{\'e}cile Fournel and V{\'e}ronique Trillet-Lenoir},
  journal={American journal of clinical oncology},
  year={2008},
  volume={31 4},
  pages={363-8}
}
BACKGROUND This open controlled prospective study aimed at evaluating the medical and economical impact of first line chemotherapy for metastatic breast cancer (MBC). PATIENTS AND METHODS Two groups of HER +++ MBC patients were compared: 26 were treated by a combination of trastuzumab and paclitaxel in 4 "prescriber" centers (group A) and 19 patients were treated by any chemotherapy without addition of trastuzumab, in 6 control centers (group B). The cost of chemotherapy and related… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Trastuzumab beyond progression: a cost-utility analysis.

Annals of oncology : official journal of the European Society for Medical Oncology • 2010

Similar Papers

Loading similar papers…